I-SPY 2 graduates two neoadjuvant treatments to phase III trials
Taking a step toward the goal of personalized medicine, investigators in the multicenter, adaptive I-SPY 2 trial report that tailoring neoadjuvant therapy combinations to specific cancer subtypes in...
Source: Family Practice News - Category: Primary Care Source Type: news
More News: Cancer | Cancer & Oncology | Family Practices | Graduation | Neoadjuvant Therapy | Primary Care